Literature DB >> 29325693

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.

Gladell P Paner1, Walter M Stadler2, Donna E Hansel3, Rodolfo Montironi4, Daniel W Lin5, Mahul B Amin6.   

Abstract

The Tumor-Node-Metastasis (TNM) classification on cancer staging, jointly developed by the American Joint Commission on Cancer (AJCC) and the Union for International Cancer Control (UICC), has been updated to its 8th edition with two contemporaneous versions published by the AJCC and UICC. While the goal of the AJCC and UICC is to have identical TNM staging systems, differences exist between these two publications including in the staging of urologic cancers. Among several new facets in the AJCC staging manual, a select few of greater import include an expanded section on imaging, presentation of levels of evidence for significant changes, and endorsement of risk assessment models that pass the AJCC quality criteria such as in prostate cancer. The updates for urologic cancers in the AJCC stage categories can be grouped into: (1) newly defined TNM categories and prognostic stage groupings, (2) clarifications and refinements of previously defined categories, and (3) more systematic and expanded presentation of prognostic factors. Changes are harmonized with the current reporting and treatment guidelines. Contributions from genitourinary pathology are evident in the AJCC classification from many of the International Society of Urological Pathology (ISUP) consensus conferences on prostate, kidney, testicular, and penile neoplasms that addressed staging issues and the timely publication of the 4th edition of the World Health Organization (WHO) classification of urinary and male genital organ tumors. New grading approaches for penile (WHO/ISUP grade), prostate (Grade group), and kidney (WHO/ISUP nucleolar grade) cancers were adopted in the AJCC system. Many of these updates in the AJCC staging manual are also included in the 8th UICC TNM edition. In an effort to achieve the optimal staging recommendations for urologic cancers, updates in the 8th TNM edition were generated through the acquisition of best evidences, tapping interdisciplinary resources including consensus recommendations, and enhanced data analysis. PATIENT
SUMMARY: In this report, we explain the seminal changes in the 8th edition of the Tumor-Node-Metastasis staging system for urologic cancers. Major stage category definitional changes are in Tumor-Node-Metastasis classifications of testicular, penile, and prostate cancer which improve patient stratification for prognosis and management.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder; Genitourinary; Kidney; Penis; Prostate; Staging; TNM; Testis; Ureter; Urethra; Urinary; Urologic

Mesh:

Year:  2018        PMID: 29325693     DOI: 10.1016/j.eururo.2017.12.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  101 in total

1.  Detection of circulating tumour cells and their potential use as a biomarker for advanced renal cell carcinoma.

Authors:  Tae Heon Kim; Yoon-Tae Kang; Young-Ho Cho; Jeong Hoon Kim; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee
Journal:  Can Urol Assoc J       Date:  2019-01-21       Impact factor: 1.862

2.  Mohs micrographic surgery for penile carcinoma with urethral invasion: A multidisciplinary approach.

Authors:  Andres M Erlendsson; Britney N Wilson; Phyllis Bellia; William Phillips; Laura Leddy; Anthony M Rossi
Journal:  J Am Acad Dermatol       Date:  2020-04-11       Impact factor: 11.527

3.  2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma.

Authors:  Yanyan Zhao; Caixia Wu; Wei Li; Xueqi Chen; Ziao Li; Xuhe Liao; Yonggang Cui; Guangyu Zhao; Meng Liu; Zhanli Fu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-19       Impact factor: 9.236

4.  Forkhead-box series expression network is associated with outcome of clear-cell renal cell carcinoma.

Authors:  Zhongwei Jia; Fangning Wan; Yao Zhu; Guohai Shi; Hailiang Zhang; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

5.  Prevalence of human papillomavirus and implication on survival in Chinese penile cancer.

Authors:  Chengbiao Chu; Keming Chen; Xingliang Tan; Jiangli Lu; Yuanzhong Yang; YiJun Zhang; Kai Yao; Yun Cao
Journal:  Virchows Arch       Date:  2020-05-19       Impact factor: 4.064

Review 6.  Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.

Authors:  Gargi Kothari; Piet Ost; Patrick Cheung; Pierre Blanchard; Alison C Tree; Nicholas J van As; Simon S Lo; Drew Moghanaki; Andrew Loblaw; Shankar Siva
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.075

7.  Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion.

Authors:  Zaosong Zheng; Dingjun Zhu; Fengjin Zhao; Jinli Han; Haicheng Chen; Yuhong Cai; Wenlian Xie
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

8.  The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre.

Authors:  Richard Naspro; Marco Finati; Marco Roscigno; Federico Pellucchi; Giovanni La Croce; Mario Sodano; Michele Manica; Daniela Chinaglia; Luigi F Da Pozzo
Journal:  World J Urol       Date:  2020-07-21       Impact factor: 4.226

9.  Pathological features of prostate cancer in men treated with robot-assisted radical prostatectomy in the Middle East.

Authors:  Saad Aldousari; Said Yaiesh; Omar Alkandari; Sundus Hussein
Journal:  J Robot Surg       Date:  2020-05-06

10.  Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival.

Authors:  Mounsif Azizi; Charles C Peyton; David C Boulware; Scott M Gilbert; Wade J Sexton
Journal:  Urol Oncol       Date:  2019-11-05       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.